瑞德西韦（GS-5734）作为 COVID-19 感染治疗选择的最新知识。
Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections.
机构信息
Sultan Moulay Slimane University of Beni Mellal, Laboratory of Chemistry, Modeling and Environmental Sciences, Polydisciplinary Faculty, 25 000 Khouribga, Morocco.
Sultan Moulay Slimane University of Beni Mellal, Laboratory of Chemistry, Modeling and Environmental Sciences, Polydisciplinary Faculty, 25 000 Khouribga, Morocco.
出版信息
J Infect Public Health. 2021 May;14(5):655-660. doi: 10.1016/j.jiph.2021.02.006. Epub 2021 Feb 20.
The management of SARS-CoV-2 has not yet been clearly determined and is based on potential therapies evaluated during the SARS-CoV and MERS-CoV outbreaks. An emerging potential therapeutic approach currently being evaluated in numerous clinical trials is the remdesivir agent, which acts on COVID-19 by interfering with key steps in the virus replication cycle. It is considered a therapeutic option to be evaluated against COVID-19, based on data on its in vitro and in vivo activity against MERS-CoV and SARS-CoV coronaviruses. In this work, we provide an overview of remdesivir's discovery, mechanism of action, and the current studies exploring its clinical effectiveness. Recommendations for its use against COVID-19 infection are also summarized.
SARS-CoV-2 的管理尚未明确确定，其依据是 SARS-CoV 和 MERS-CoV 爆发期间评估的潜在疗法。目前正在众多临床试验中评估的一种新兴潜在治疗方法是瑞德西韦药物，它通过干扰病毒复制周期中的关键步骤来作用于 COVID-19。根据其对 MERS-CoV 和 SARS-CoV 冠状病毒的体外和体内活性数据，瑞德西韦被认为是一种有待评估的 COVID-19 治疗选择。在这项工作中，我们提供了瑞德西韦的发现、作用机制以及目前探索其临床疗效的研究概述。还总结了针对 COVID-19 感染使用瑞德西韦的建议。
Zotero 插件